GSK's linerixibat meets primary endpoint
GSK
1,320.00p
16:54 20/12/24
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus in primary biliary cholangitis.
FTSE 100
8,084.61
17:04 20/12/24
FTSE 350
4,463.29
17:14 20/12/24
FTSE All-Share
4,421.11
17:04 20/12/24
Pharmaceuticals & Biotechnology
19,761.12
17:14 20/12/24
GSK said the GLISTEN Phase III trial of linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter in adults with a "relentless itch" associated with a rare autoimmune liver disease, had met its primary endpoint, with a "statistically significant improvement" in itch over 24 weeks compared with placebo.
The London-listed firm highlighted that linerixibat now has the potential to be the first global therapy indicated to treat itch in primary biliary cholangitis.
GSK's Kaivan Khavandi said: "Linerixibat has the potential to be the first global therapy specifically developed to treat itch in PBC. These positive data suggest that it could have a place in supporting patients whose quality of life is significantly affected in multiple ways by persistent itching."
As of 0920 GMT, GSK shares were down 0.31% at 1,306.0p.
Reporting by Iain Gilbert at Sharecast.com